Early Identification of MS Risk via EBNA-1381-452 Antibodies

This research investigates the connection between Epstein-Barr Virus (EBV) antibodies, specifically EBNA-1381-452, and Multiple Sclerosis (MS) risk. Early identification of MS is explored through biomarker analysis. The study examines antibody titers in MS patients, highlighting their prognostic value and comparison with other biomarkers. Findings suggest potential clinical applications for early MS screening and emphasize the importance of continuing research to refine methodologies.